Почетна › Рак јајника › Јута
Kliničke studije za Рак јајника u državi Јута
30 studija za Рак јајника traži učesnike na lokacijama u državi Јута.
Gradovi u državi Јута
Zvanični tekst studije (na engleskom)
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07001748A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- South Jordan Health Center, South Jordan
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06580314A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Тражи се учесник
Узраст од 35 до 50 · Жене · Ажурирано 6. 11. 2026. · NCT04251052A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Huntsman Cancer Institute, Salt Lake City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213804Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- START Mountain Region, West Valley City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Utah Cancer Specialists, South Jordan
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07564141FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- START Mountain Region, West Valley City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06303505A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- START Center for Cancer Research, West Valley City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07109726Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Utah Cancer Specialists Network, Salt Lake City
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 28. 10. 2026. · NCT06819007A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Research Site, Salt Lake City
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 16. 10. 2026. · NCT07816666A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Start Mountain Region /ID# 278609, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07278336A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Utah Cancer Specialists, Salt Lake City
Тражи се учесникФаза 2
Узраст од 18 до 99 · Жене · Ажурирано 15. 9. 2026. · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT05059444A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- START Mountain, Salt Lake City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07470853Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 8. 2026. · NCT05985655First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT07517198Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 30. 4. 2026. · NCT05297734The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
- Huntsman Cancer Institute, Salt Lake City
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 21 и старији · Жене · Ажурирано 9. 4. 2026. · NCT06665945A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- START Center for Cancer Care - Mountain Region, Salt Lake City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 27. 3. 2026. · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- LDS Hospital, Salt Lake City
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 3. 2. 2026. · NCT06469281SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.